Mark McVeigh was a 200+ game player & VC of Essendon FC.
Worked with junior players for years inc GWS Academy & Allies coach. Made his way up to GWS as assistant & eventually senior assistant. Now with Swans since 2022.
If he is the coach. You have my full 100% support Mark🖤❤️
🚨 New head-to-head RCT in @NEJM: apixaban vs rivaroxaban 🥊
🏆 Apixaban emerges as the safe winner, with half the risk of bleeding complications
💡 For patients at high risk of GI bleeding, apixaban may be preferrable to rivaroxaban
https://t.co/Drqxr1kDu4
In an international, randomized trial involving patients with acute venous thromboembolism, the risk of clinically relevant bleeding was significantly lower with apixaban than with rivaroxaban during the 3-month treatment period.
Full COBRRA trial results: https://t.co/tvPYrBCWj8
IF Caro’s report is true: The AFL stopped pumping money into grassroots because clubs have had an incentive. Think there’s an indigenous participation crisis now? Oh boy. Plus northern states - 700 kids in the Swans Academy alone training all across Sydney. Go fund it 🤷#AFLDraft
Is this the end of rivaroxaban for acute VTE?
@LanaCastellucci presenting the COBBRA trial - 1st RCT comparing apixaban to riva over 3 months.
56% reduction in bleeding risk with apixaban.
A safer Rx with the same efficacy.
#ISTH2025
Just out: Paradigm changing AQUILA randomized trial in high risk smoldering myeloma #ASH24@thanosdimop@NEJM
Daratumumab significantly prolongs time to active myeloma and overall survival. Proud to be a lead investigator of this trial https://t.co/NMnjBytzQT
Slides in thread
Caitlin Rice presenting her data on type 3 VWD in Australia. Great to see work being done to understand this group with clear understanding of met needs. The burden of treatment remains high. @THANZBlood
Vice President Kamala Harris is on the brink of being the Democratic candidate for November’s US election, despite failing to secure an immediate endorsement from Barack Obama. https://t.co/RW2mBfnQau
New @ISTH#haemophilia guidelines have been subject to a last minute amendment to recommend prophylaxis with either emicizumab or factor VIII concentrates after public consultation elicited a high level of feedback.
#isth2024@JTHjournal
https://t.co/pcaYeh2yf6
* Yearly scheduled tweet *
Matt Keenan on the Tour De France broadcast last night identified a Slovakian cyclist in a group of 150 riders from a helicopter shot.
Meanwhile, Brian Taylor has called Bobby Hill “Bobby Jones” three times tonight.
1- Mezagitamab for chronic/persistent ITP (LB01.1)
New anti-CD38 for #ITP. Most of patients heavily pretreated (mean of 3.9 prior lines). Good responses (more than 90% of platelet response in the 600 mg arm), fast improvement (less than 2 weeks) and few IP related TEAEs (7%).